The topic of metastatic castration-sensitive prostate cancer has been on the forefront of clinical research in prostate cancer for many years now. In 2017, and again in 2019, I wrote Clinical Trials Portal articles on the topic of metastatic castration-sensitive prostate cancer, summarizing the key ongoing trials during those times.1, 2 We now know that […]
San Francisco, CA (UroToday.com) — Movember, in collaboration with Prostate Cancer UK, is bringing together researchers from around the world in a bid to establish the best way of treating men with high-risk, aggressive prostate cancer and extending their lives by preventing their disease from reaching an advanced stage.
Christopher Wallis: Hello, and thank you for joining us for this UroToday Journal Club presentation. Today we are discussing a recent publication titled, Underutilization of Blue Light Cystoscopy for Bladder Cancer in the United States. I’m Chris Wallis, Assistant Professor in the Division of Urology at the University of Toronto. With me today is Zach […]
Alicia Morgans: Hi, my name is Alicia Morgans, and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I am so excited to have here with me today, Dr. Susan Halabi, who is the Professor and the Co-chief of the Division of Biostatistics at Duke in Durham, North Carolina. And Dr. Dana Rathkopf, who is […]
Several clinicopathological features of clear cell renal cell carcinomas (ccRCC) contribute to make an "atypical" cancer, including resistance to chemotherapy, sensitivity to anti-angiogenesis therapy and ICIs despite a low mutational burden, and CD8+ T cell infiltration being the predictor for poor prognosis-normally CD8+ T cell infiltration is a good prognostic factor in cancer patients.
Renal cell carcinoma (RCC) is among the 10 most common cancer entities and can be categorised into distinct subtypes by differential expression of Krebs cycle genes. We investigated the predictive value of several targeted metabolites with regards to tumour stages and patient survival in an unselected cohort of 420 RCCs.
Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses.
There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy (SBRT). The aim of the present study was to explore 4-year prostate-specific antigen response rate (4yPSARR) as an early predictive measure.
Magnetic resonance imaging (MRI)/ultrasound-fusion prostate biopsy (FB) comprises multiple steps each of which can cause alterations in targeted biopsy (TB) accuracy leading to false-negative results.
Prostate cancer (PCa) is the second most common malignant cancer and is a major cause of morbidity and mortality among men worldwide. There is still an urgent need for biomarkers applicable for diagnosis, prognosis, therapy prediction, or therapy monitoring in PCa.
